Has Cosentyx Been Linked to Stroke Risk?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries a boxed warning for increased risk of serious infections, but stroke is not listed as a primary warning in its U.S. prescribing information.[1] Post-marketing reports and clinical data show rare cerebrovascular events, including ischemic stroke, but no definitive causal link has been established by regulators like the FDA or EMA.
What Do Clinical Trials Show?
In phase 3 trials (e.g., FUTURE, MEASURE, CLEAR), stroke occurred in fewer than 0.5% of Cosentyx patients, similar to placebo rates (0.2-0.4%).[2] Pooled safety data from over 10,000 patients reported 21 cerebrovascular accidents (0.2%), mostly in patients with cardiovascular risk factors like hypertension or prior events.[3] No dose-response pattern emerged, suggesting these may reflect underlying disease risks rather than the drug.
What About Real-World Evidence and Post-Approval Reports?
FDA Adverse Event Reporting System (FAERS) data through 2023 logs over 100 stroke reports with Cosentyx, but underreporting and confounding factors (e.g., age >50, comorbidities) limit causality.[4] A 2022 Swedish registry study of 12,000 psoriasis patients found no significant stroke risk increase with IL-17 inhibitors vs. other biologics (HR 1.1, 95% CI 0.7-1.7).[5] Observational data from CorEvitas registry (2024) noted transient ischemic attacks in 0.3% of users, aligned with population baselines.[6]
Why Might Strokes Occur in Patients Taking Cosentyx?
IL-17 inhibition modulates inflammation, potentially affecting vascular plaques, but evidence is mixed—some animal models suggest reduced atherosclerosis, while human data shows neutral effects.[7] Most reported cases involve older patients (mean age 65) with risks like diabetes, smoking, or atrial fibrillation, common in treated populations. No mechanism directly implicates Cosentyx over disease itself.
How Does This Compare to Other Biologics?
| Drug | Stroke Incidence in Trials/Registries | Key Notes |
|------|--------------------------------------|-----------|
| Cosentyx | 0.2-0.5% | No signal vs. placebo |
| Humira (adalimumab) | 0.3-0.6% | Similar; TNF inhibitors have CV warnings in heart failure |
| Stelara (ustekinumab) | 0.1-0.4% | Lowest rates; IL-12/23 inhibitor |
| Skyrizi (risankizumab) | <0.3% | Comparable IL-23 data |
TNF inhibitors like Humira show slightly higher signals in some registries (HR 1.2-1.5), possibly due to broader immunomodulation.[8] No class-wide stroke alert for IL-17/IL-23 drugs.
What Do Regulators and Labels Say?
FDA and EMA labels mention "cerebrovascular events" under serious adverse reactions but do not quantify stroke risk or require monitoring beyond standard CV assessments.[1][9] No updates post-2023 label revisions. Novartis reports no new safety signals in ongoing surveillance.
Should Patients Worry and What Precautions Apply?
Absolute risk remains low (<1/1,000 patient-years), driven more by patient factors than Cosentyx.[3] Guidelines recommend CV risk screening before starting (e.g., ASCVD score) and lifestyle management. Discontinue if acute stroke occurs; rechallenge data is limited. Consult providers for personalized risk, especially with history of stroke or clots.
Sources
[1]: Cosentyx Prescribing Information (FDA)
[2]: NEJM 2014; FUTURE 1 Trial
[3]: Novartis Safety Update 2022
[4]: FAERS Public Dashboard (FDA)
[5]: JAMA Dermatol 2022; Swedish Registry
[6]: J Am Acad Dermatol 2024; CorEvitas
[7]: Circ Res 2019; IL-17 Review
[8]: Ann Rheum Dis 2021; Meta-Analysis
[9]: EMA Product Information